Abstract
This is the latest RNAi-based Therapeutics Market Report from Select
Biosciences. This report presents an up-to-date thorough analysis of the RNAi
therapeutics landscape based upon our continuing coverage of this dynamic
marketplace. This report presents an exhaustive analysis of all the
therapeutics areas where research efforts using RNAi-based therapeutics are
being focused: From Research/Pre-Clinical through Phase III Clinical Trials.
Select Biosciences proprietary market survey addresses druggability trends,
drug target classes (where RNAi therapeutics will impact) and different
therapeutic areas in terms of challenges/opportunities/quantitative industry
metrics-this highly valuable dataset is based on an extensive market analysis.
An extensive analysis of the Intellectual Property (IP) landscape in RNAi
therapeutics space, RNAi technology trends, and relevant company profiles make
this report a complete and timely industry analysis.
Topics Covered in this Report
- Opportunities and challenges in the RNAi therapeutics space
- Therapeutics areas impacted by RNAi therapeutics: Timeline for impact,
top-most challenge in each therapeutic area
- Different target classes and their amenability to targeting using RNAi
therapeutics
- Top-most drug target class for RNAi therapeutics
- Delivery approach by therapeutic area
- Factors that determine whether a given target will be druggable via
RNAi-based therapeutics
- Opportunities for vendors in the space
- Research/Pre-Clinical, Phase I, Phase II, and Phase III RNAi therapeutics
Clinical Trials: Details by company, molecular target, therapeutic/disease
area, partnership[s]
- Technology trends in the RNAi space
- Intellectual property (IP) in the RNAi therapeutics space: Landscape and
discussion of the various key patents
- Relevant company profiles: Partnerships, therapeutics/trials pipeline
| 
View Cart
